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ABSTRACT 
Understanding the in vivo behavior of experimental therapeutic cells is fundamental to their 
successful development and clinical translation. Iodine-124 has the longest half-life (4.2 days) 
among the clinically used positron emitters. Consequently, this isotope offers the longest 
possible tracking time for directly labeled cells using positron emission tomography (PET). 
Herein, we have radiosynthesized and evaluated two iodine-124/fluorescein-based dual PET 
and fluorescent labeling reagents; namely 124I-FIT-Mal and 124I-FIT-(PhS)2Mal for cell surface 
thiol bioconjugation. 124I-FIT-(PhS)2Mal labeled cells significantly more effectively than 124I-
FIT-Mal. It conjugated to various cell lines in 22%-62% labeling efficiencies with prolonged 
iodine-124 retention. 124I-FIT-(PhS)2Mal was mainly conjugated on the cell membrane 
confirmed by high-resolution fluorescence imaging. The migration of 124I-FIT-(PhS)2Mal 
labeled Jurkat cells was visualized in NSG mice with excellent target-to-background contrast 
using PET/CT over 7 days. These data demonstrate that 124I-FIT-(PhS)2Mal can dynamically 
track cell migration in vivo using PET/CT over a clinically relevant timeframe.  
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INTRODUCTION 
Emerging as the fourth pillar of healthcare, cell-based therapies have shown great promise in 
cancer treatment,1 stem cell regenerative medicine,2 and immune tolerance in organ 
transplantation.3 For example, adoptive transfer of chimeric antigen receptor (CAR)-
engineered T-cells is a novel immunotherapy that utilizes the patient’s own immune system to 
treat cancer.4 One fundamental challenge in both medical research and clinical applications of 
cell therapies is to understand the in vivo behavior of the infused cells. Imaging studies can 
dynamically track the migration, proliferation, and final fate of the administered cells providing 
early insight into their safety, mechanism of action, and efficacy.5,6 Therefore, it is essential to 
incorporate tracking studies at the earliest stage of clinical development in order to monitor the 
in vivo location and persistence of the cells on a patient-by-patient basis.5,6  
To detect the initial distribution and migration of the infused cells, various direct cell labeling 
methods have been developed by which the therapeutic cells are labeled with a contrast reagent 
in vitro. Once inoculated into the experimental animals or patients, the movement of the labeled 
cells can be monitored using the corresponding imaging modality.7-10 Positron emission 
tomography (PET) is a non-invasive imaging technique that can produce real-time images of 
radiolabeled cells in vivo and monitor their whole-body migration.11 Currently, the most 
successful direct cell labeling method for PET involves the use of lipophilic radiometal 
complex, 89Zr(oxine)4 to deposit 89Zr intracellularly.12,13 Owning to the 3.3 days half-life of 
89Zr, this method has been employed to track a variety of cells for several days in vivo. 
Alternatively, an 89Zr-desferrioxamine-isothiocyanate bioconjugation reagent was reported to 
label cells through the amine groups in cell surface proteins, allowing the assessment of the 
distribution of the labeled cells in vivo for days.14 However, when applying both of the above 
89Zr based cell tracking methods to monitor the experimental therapeutic cells in preclinical 
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settings, the 89Zr leaks gradually from the labeled cells in vivo and deposits in bones, 
complicating the interpretation of PET images.10,11,13,14   
Iodine-124 has the longest half-life (t1/2 = 4.2 d) among the clinically used PET radioisotopes.15 
In principle, it can provide the longest possible tracking time for directly labeled cells with 
PET. In addition, the thyroid and stomach uptake of any free iodine-124 generated through the 
catabolism of the labeling reagent can be readily blocked by pre-treatment with potassium 
iodide. Consequently, this approach provides a low background that will improve the 
sensitivity and accuracy to detect the labeled cells. However, the major challenge with the use 
of iodine-124 based reagents for direct cell labeling is how to overcome various intracellular 
oxido-reductase-mediated deiodination.15 We envisage that the deiodination can be minimized 
by coupling the iodine-124 on the cell surface. For this purpose, we choose thiols present in 
cell membrane proteins for labeling because they have been proven to be ideal functional 
groups in various bioconjugation applications.16,17 To achieve both effective cell conjugation 
and minimum the passive diffusion of labeling reagents into cells, we hypothesize that the 
labeling reagents should be amphiphiles in nature. In this context, such reagents will be 
equipped with a lipophilic warhead to reach and react with thiols in the lipid surrounded cell 
surface proteins. They will also contain a negatively charged hydrophilic moiety that will 
repulse the negatively charged phosphate heads of the membrane lipids to minimise the 
labeling reagents diffusing into cells. In addition, a fluorophore will also be employed to 
confirm effective cell surface conjugation with fluorescence imaging. To achieve these goals, 
we selected two thiol-targeting moieties, maleimide and dithiophenolmaleimide for cell surface 
conjugation. The maleimide reacts irreversibly with the free thiols on the cell surface as 
demonstrated by others.16,17 The dithiophenolmaleimide spontaneously reacts with both thiols 
from the reduced disulfide bridge and preserves the bridge structure in antibodies and 
peptides.18,19 Although never been applied to cell labeling before, we envisaged that these 
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characteristics of dithiophenolmaleimide would enable it to conjugate to the cell surface 
proteins effectively with minimal adverse effects. We selected fluorescein as the fluorescent 
reporter for this application since it is used clinically in man and thus should exert negligible 
toxicity. Moreover, the carboxylic acid group of this hydrophilic dye is deprotonated and 
becomes negatively charged at physiological pH, which would retard the labeling reagent from 
entering cells.  
Herein, using a copper mediated one-pot three-component radioiodination reaction,20-22 we 
synthesized two trifunctional dual PET and fluorescent bioconjugation reagents, 124I-FIT-Mal 
[1] and 124I-FIT-(PhS)2Mal [2]. These are equipped with: (i) iodine-124 for longitudinal cell 
tracking with PET; (ii) a hydrophilic fluorescein moiety to balance lipophilicity and enable 
fluorescence cell imaging; (iii) a maleimide or dithiophenolmaleimide moiety for cell 
membrane protein thiol bioconjugation.  
RESULTS  
Synthetic chemistry and radiolabeling 
Initially, the fluorescein isothiocyanate isomer I was reacted with 2-azidoethan-1-amine to 
generate the 5-[3-(2-azidoethyl)thioureido]-fluorescein in 82% yield. This was then converted 
to the 5-[3-(2-azidoethyl)ureido]-fluorescein [3] using pyridinium tribromide (two equivalents) 
in 63% yield.23 The N-propargyl maleimide [4]21 and the N-propargyl-3,4-
dithiophenolmaleimide [5]24 were prepared according to published methods. Subsequently, the 
nonradioactive reference compound of 124I-FIT-Mal [1] was synthesized by the copper (I) 
mediated one-pot three-component reaction from 5-[3-(2-azidoethyl)ureido]-fluorescein [3], 
N-propargyl maleimide [4], and N-iodosuccinimide (NIS) in 56% yield. Similarly, the 
nonradioactive reference compound of 124I-FIT-(PhS)2Mal [2] was prepared by reacting 5-[3-
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(2-azidoethyl)ureido]-fluorescein [3] with N-propargyl-3,4-dithiophenolmaleimide [5], and 
NIS in 45% yield (Scheme 1). 
Next, the 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] were radiosynthesized using a one-pot 
three-component radioiodination reaction. The 5-[3-(2-azidoethyl)ureido]-fluorescein [3] and 
either N-propargyl maleimide [4] or N-propargyl-3,4-dithiophenolmaleimide [5] was reacted 
with [124I]NaI in a catalytic system of CuCl2/Et3N/bathophenanthroline (10 mol%) (Scheme 1). 
Excellent radiochemical yields (RCYs) of 81±6 % (n=6) and 71±1% (n=7) were obtained for 
124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] respectively, as determined by HPLC (Figure S1 
and S3). The isolated RCYs for 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] were 60±6% (n=6) 
and 53±1% (n=7), respectively. The identities of 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] 
were confirmed by the co-elution with their corresponding nonradioactive reference 
compounds (Figure S2 and S4). The molar activities of 124I-FIT-Mal [1] and 124I-FIT-
(PhS)2Mal [2] were about 2.30 GBq/µmol and 1.30 GBq/µmol, respectively, when started with 
~10 MBq of iodine-124. The log D for 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] was 
measured by a conventional partition method between n-octanol and pH 7.4 PBS as -0.72±0.02 
and 1.42±0.09 (n=6), respectively.  
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(i) 2-azidoethan-1-amine, TEA, DCM/THF, 0 ºC to RT in 3 h, 82%; (ii) pyridinium tribromide 
(2.0 equiv.), THF/H2O, RT, 3 h, 63%; (iii) a) CuI, TEA, NIS, DMF, 18 h; when I*=127I; or b) 
CuCl2, TEA/TEA·HCl, bathophenanthroline (10 mol%), [124I]NaI, DMF/CH3CN/H2O; when 
I*=124I. 
Scheme 1. Synthesis of the dual PET and fluorescent labeling reagents  
Cell radiolabeling efficiency and cellular localization of the dual labeling reagents  
Immortalized Jurkat human T cell lymphoma cells (5 x 106) were incubated with 124I-FIT-Mal 
[1] or 124I-FIT-(PhS)2Mal [2] in PBS at 37 ºC for 30 min. Low labeling efficiencies of 4±1% 
and 11±1%, (n=3) for 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2], respectively, were observed. 
In parallel experiments, Jurkat cells (5 x 106) were pre-treated with tris(2-
carboxyethyl)phosphine (TCEP) (1.0 mM), a disulfide bridge reducing reagent in PBS for 15 
min. The TCEP was then removed before incubating the cells with 124I-FIT-Mal [1] or 124I-
FIT-(PhS)2Mal [2] in PBS at 37 ºC for another 30 min. Significantly increased cell labeling 
efficiencies of 11±1% and 22±1%, (n=3) for 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2], 
respectively, were achieved (Figure 1A). As 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells much 
more effectively than 124I-FIT-Mal [1], it was further tested to label murine myeloma 5T33 
cells and human peripheral blood T-cells. By pre-treating both cell lines (5 x 106) with TCEP 
and then incubating with 124I-FIT-(PhS)2Mal [2], cell labeling efficiencies of 62±1% and 
27±2%, (n=3), respectively, were obtained. Once again, lower cell labeling efficiencies of 44±4% 
and 17±1%, (n=3) for the 5T33 cells and human T-cells, respectively, were observed without 
TCEP pre-treatment (Figure 1B). To investigate the cellular localization of 124I-FIT-(PhS)2Mal 
[2], Jurkat, 5T33, and human T-cells were incubated with the nonradioactive reference 
compound of 124I-FIT-(PhS)2Mal [2] (1.0 µM) after TCEP pre-treatment. The labeled cells 
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were then observed under a confocal fluorescence microscope. Green fluorescent signals were 
mainly distributed on the cell membrane for all three cell lines (Figure 2).  
 
Figure 1. Cell labeling efficiencies of 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] with Jurkat 
cells (A); cell labeling efficiencies of 124I-FIT-(PhS)2Mal [2] with Jurkat, 5T33, and human T-
cells (B). (% incubation dose per 5 x 106 cells, mean±SD, n=3 independent replicates).  
 
Figure 2. Confocal fluorescence images of the non-radioactive reference compound of 124I-
FIT-(PhS)2Mal [2] labeled Jurkat, 5T33, and human T-cells. Nuclei were counterstained with 
Hoechst 33342. (Scale bar = 20 µm)  
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Jurkat cell 124I-retention, viability, proliferation, and cytokine release post radiolabeling    
We investigated the retention of iodine-124 by the 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells 
(~100 KBq/106 cells) when cultured for 7 days in complete cell medium. 124I-FIT-(PhS)2Mal 
[2] labeled Jurkat cell viability, proliferation, and interleukin-2 (IL-2) release, was also 
monitored and compared with unlabeled Jurkat cells. After an initial rapid loss of about 25% 
radioactivity in the first 24 hours, the dissociation of iodine-124 from the labeled Jurkat cells 
was very slow. Notably, 65±3% (n=6) of total radioactivity was still retained in the Jurkat cells 
7 days post labeling (Figure 3A). Cell viability was similar to the unlabeled Jurkat cells as 
determined by the Trypan Blue exclusion assay (Figure 3B). Proliferation of 124I-FIT-
(PhS)2Mal [2] labeled Jurkat cells (~100 KBq/106 cells) was determined using the CCK-8 assay, 
which measures the dehydrogenase metabolic activity of proliferating cells. There is no 
statistically significant difference between the proliferation rates of labeled and unlabeled 
Jurkat cells over 7 days (Figure 3C). To determine Jurkat cell function post radiolabeling, 124I-
FIT-(PhS)2Mal [2] labeled (~100 KBq/106 cells) or unlabeled Jurkat cells were treated with or 
without PMA/ionomycin for 24 h. The IL-2 generated was then measured using ELISA. Both 
labeled and unlabeled Jurkat cells produced similar amount of IL-2 upon stimulation, while 
little IL-2 was generated in the absence of PMA/ionomycin (day 6) (Figure 3D). 
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Figure 3. Retention of iodine-124 (A), cell viability (B), cell proliferation by CCK-8 assay (C), 
and IL-2 production with (+) and without (-) PMA/ionomycin activation by ELISA assay (D) 
of 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells (~100 KBq/106 cells, mean±SD, n=6 for A and 
B; n=3 for C and D, independent replicates). Unlabeled cells serve as control.  
In vivo cell tracking with PET imaging and biodistribution study  
Subsequently, we carried out a tracking study of 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells 
(~0.5-1.0 x 107 cells, ~0.5-1.0 MBq) in NSG mice (n=3) by five sequential PET/CT scans at 4 
h, 24 h and 2, 5, and 7 days post intravenous (IV) injection. Radioactivity accumulated mainly 
in the lungs, liver, and bladder in the 4 and 24 h PET/CT images. The radioactivity gradually 
migrated from the lungs to the liver and cleared from the bladder in the NSG mice in the day 
2, 5, and 7 PET/CT images (Figure 4A). After completion of PET/CT imaging on day 7, all 
three animals were euthanized for a biodistribution study. Radioactivity uptake of 7.90±0.88%, 
2.94±0.28%, and 2.38±0.74% injected dose (ID)/g, was detected in lungs, liver, and spleen 
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respectively (mean+SD, n=3). Radioactivity uptake in other organs such as blood and bone etc. 
were all less than 1% ID/g (Figure 5A and Table S1). In the control group, NSG mice (n=4) 
received the dual labeling reagent, 124I-FIT-(PhS)2Mal [2] IV and underwent a PET/CT scan 
after 24 h. Most of the radioactivity had cleared from the animals and only very weak 
radioactivity signals were observed in the large intestine and bladder, as shown in the 24 h 
PET/CT image (Figure 4B). All four animals were euthanized after PET/CT imaging for a 
biodistribution study. Minimal radioactivity was detected in the lungs (0.88±0.20% ID/g), liver 
(0.63±0.09% ID/g), and spleen (0.44±0.05% ID/g) of these animals (Figure 5B and table S2). 
 
Figure 4. Representative PET/CT images of NSG mice that received either 124I-FIT-(PhS)2Mal 
[2] labeled Jurkat cells at 4, 24 hours, 2, 5, and 7 days (n=3) (A) or 124I-FIT-(PhS)2Mal [2] at 
24 hours post IV injection (n=4) (B). All animals were treated with potassium iodide one week 
before and throughout the PET/CT imaging experiments. 
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Figure 5. Biodistribution analysis of NSG mice that received either 124I-FIT-(PhS)2Mal [2] 
labeled Jurkat cells on day 7 post IV injection (mean±SD, n=3) (A) or 124I-FIT-(PhS)2Mal [2] 
at 24 h post IV injection (mean±SD, n=4) (B). All animals were treated with potassium iodide 
one week before until the day of the biodistribution study.  
Ex vivo immunohistochemistry study  
Finally, we undertook immunohistology staining of liver and lung tissues harvested from NSG 
mice that were inoculated with 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells in the PET imaging 
study. As controls, the liver and lungs from three NSG mice received either PBS or non-labeled 
Jurkat cells (~1.0 x 107), respectively, were collected for immunohistology staining 7 days post 
IV injection. All tissue sections were sequentially incubated with anti-human CD3 as the 
primary antibody and polymer-supported peroxidase/anti-Mouse IgG as followed by the 3,3′-
diaminobenzidine (DAB) treatment. Both 124I-FIT-(PhS)2Mal [2] labeled and non-labeled 
Jurkat cells migrated to the liver and lung tissues from the NSG mice either used in the PET 
imaging study or the positive control group were stained brown in colour (Figure 6, labeled 
or non-labeled Jurkat). In contrast, the anti-human CD3 staining was negative in the liver 
and lung tissues from the PBS-treated NGS mice in the negative control group (Figure 6, PBS).   
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Figure 6. Representative immunohistochemistry images: liver and lung tissues collected from 
the NSG mice (n=3) received either 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells, PBS, or non-
labeled Jurkat cells 7 days post IV injection. Tissue sections were counterstained with 
hematoxylin. (Scale bar = 200 µm for 10x or 50 µm for 40x) 
DISCUSSION  
Initially, the nonradioactive reference compounds of 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal 
[2] were synthesized in moderate yields using copper mediated one-pot three-component click 
reactions. It proved essential to use 5-[3-(2-azidoethyl)ureido]-fluorescein [3] rather than its 
corresponding 5-[3-(2-azidoethyl)thioureido]-fluorescein formed in the first synthetic step in 
Scheme 1. No desired iodotriazoles were formed when 5-[3-(2-azidoethyl)thioureido]-
fluorescein was used. This is because thioureas are susceptible to copper(II) oxidation.25 In 
terms of radiosynthesis, a longer reaction time of 18 hours at RT was required to prepare 124I-
FIT-Mal [1] in both excellent RCYs and molar activity. When radiolabeling was attempted at 
 
 
 
14 
 
elevated temperature, the formation of both radioactive and non-radioactive side-products were 
observed, which significantly reduced the RCYs and molar activity of 124I-FIT-Mal [1]. As 
iodine-124 has a half-life of 4.2 days, we decided to adopt the longer reaction time for the 
preparation of 124I-FIT-Mal [1]. In contrast, 124I-FIT-(PhS)2Mal [2] was formed in both 
excellent RCYs and molar activity in 90 min which allows its production, cell labeling, and 
subsequent biological evaluation in a clinically relevant time frame. Control radiolabeling 
experiments in the absence of the alkynes [4] and [5] were also conducted and only the free 
iodine-124 was observed, which indicated that phenolic ring of the fluorescein moiety cannot 
be radioiodinated under the conditions used to prepare both dual labeling reagents. 
Subsequently, we investigated Jurkat cell conjugation with 124I-FIT-Mal [1] and 124I-FIT-
(PhS)2Mal [2] without or with pre-treatment of the cells using a mild reducing agent, TCEP. It 
has been used to increase cell surface free thiols for maleimide conjugation on various cell lines 
including stem cells and cancer cells without adverse effect on cell functions.16,26 The cell 
labeling efficiencies achieved for both 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] were 
significantly improved by pre-treating the cells with TCEP which boosts the amount of cell 
membrane free thiols. The cell labeling efficiency for 124I-FIT-(PhS)2Mal [2] was one-fold 
higher than that of 124I-FIT-Mal [1]. One possible reason is that 124I-FIT-(PhS)2Mal [2] is 
lipophilic which makes it more accessible to lipid surrounded cell membrane proteins. In 
contrast, the hydrophilic nature of 124I-FIT-Mal [1] would be expected to repel it from the cell 
membrane. The general utility of 124I-FIT-(PhS)2Mal [2] for cell labeling was subsequently 
demonstrated by its successful conjugation to the murine myeloma 5T33 cells and to human 
peripheral blood T-cells. Significantly higher cell labeling efficiency was observed for the 
5T33 cells compared to Jurkat cells and human T-cells. This is likely due to the higher numbers 
of thiols associated with 5T33 cell surface proteins as determined by the DTNB assay 
(supporting information). The cell membrane localization of 124I-FIT-(PhS)2Mal [2] on all three 
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cell lines was confirmed by confocal fluorescence imaging. Despite its lipophilic nature, the 
124I-FIT-(PhS)2Mal [2] was mainly deposited on the cell membrane. This is likely resulting 
from the amphiphilic characteristics of this molecule. The fluorescein moiety in 124I-FIT-
(PhS)2Mal [2] is negatively charged due to the deprotonation of its carboxylic acid group in 
PBS (pH 7.4), which repels this part of the molecule from the negatively charged cell 
membrane. Meanwhile, the lipophilic dithiophenolmaleimide moiety in 124I-FIT-(PhS)2Mal [2] 
is attracted by the cell membrane lipids. These combined forces allow 124I-FIT-(PhS)2Mal [2] 
to reach cell membrane protein thiols for conjugation rather than rapidly entering the cells 
through passive diffusion. Moreover, 124I-FIT-(PhS)2Mal [2] has shown remarkable radiolabel 
retention at a radioactivity level of 100 KBq/106 Jurkat cells, with minimum effect on cell 
viability. About 65% of radioactivity was still associated with the Jurkat cells in vitro even 7 
days post radiolabeling with 124I-FIT-(PhS)2Mal [2]. This level of radioactivity retention and 
tolerance is comparable with that observed following 89Zr(oxine)4 labeling of CAR T-cells. In 
those cases, 40-80% of 89Zr was retained for 5-7 days post labeling while tolerated radioactivity 
doses ranged from 30-70 KBq/106 cells.10-13 Notably, about 25% of the radioactivity was lost 
in the first 24 hours post labeling followed by the very slow loss of radiolabel from the Jurkat 
cells, about 7% in six days. Due to the lipophilicity of 124I-FIT-(PhS)2Mal [2], it would be 
expected to interact non-covalently with cell membrane lipids which would cause rapid 
dissociation of 124I-FIT-(PhS)2Mal [2] from the cells. In contrast, covalently bonded 124I-FIT-
(PhS)2Mal [2] showed greater stability. In addition, faint green color was observed inside the 
cells in the confocal fluorescence images (Figure 3) indicating a small portion of 124I-FIT-
(PhS)2Mal [2] did enter the cells, which could also rapidly diffuse out of the cells through 
passive diffusion.   
Jurkat cells are leukaemic T-cells that produce IL-2 upon PMA/ionomycin stimulation. When 
labeled with 124I-FIT-(PhS)2Mal [2] at a radioactivity dose of about 100 KBq/106 cells, IL-2 
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production is similar to unlabeled control Jurkat cells. In addition, cell proliferation is also 
largely unaffected post 124I-FIT-(PhS)2Mal [2] labeling. Thus, Jurkat cell functions, in terms of 
IL-2 production and cell proliferation, are reserved at this radioactivity dose. 
In the proof of concept in vivo tracking study, the migration of 124I-FIT-(PhS)2Mal [2] labeled 
Jurkat cells from the lungs to the liver was clearly visualized in NSG mice using five 
consecutive PET scans over 7 days. Spleen is a major cell migration organ we expected to 
observe in PET. However, the high liver radioactivity uptake and the anatomical proximity 
between liver and spleen completely obscured the spleen in the PET images. It is worth noting 
that in contrast to the high bone uptake of 89Zr-based cell tracking reagents,10,11,13,14 no bone 
uptake was observed in all five PET images from 4 hours until 7 days post IV injection of 124I-
FIT-(PhS)2Mal [2] labeled Jurkat cells. This illustrates the superiority of this iodine-124 based 
strategy over the current zirconium-89 methods for direct cell labeling and long-term cell 
tracking with PET. As expected, thyroid and stomach uptake of iodine-124 were completely 
blocked by treating the animals with potassium iodide, generating a clear background for 
visualization of cell migration. Moreover, the initial dissociation of the labeling reagent from 
the Jurkat cells was observed in the 4 and 24 hour PET images, as indicated by the accumulation 
of radioactivity in the bladder. However, little radioactivity was observed in the bladder at later 
time points (2, 5, and 7 days), indicating that the labeling reagent was still associated with the 
Jurkat cells. These observations are in good agreement with the in vitro iodine-124 retention 
from the 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells. The biodistribution study undertaken on 
NSG mice 7 days post inoculation of 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells also provided 
strong evidence that the radioactivity was still concentrated in the organs to which the cells 
migrated. These include the lungs, liver, and spleen, with little radioactivity detected in other 
organs at this late time point. In contrast, in the control group that had received 124I-FIT-
(PhS)2Mal [2], both PET/CT imaging and a biodistribution study confirmed that most of the 
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radioactivity was cleared from the NSG mice within 24 h post IV injection. Moreover, the 
presence of Jurkat cells in the lungs and liver of the NSG mice that received 124I-FIT-(PhS)2Mal 
[2] labeled Jurkat cells from the PET imaging was further confirmed using antihuman CD3 
antibody in an ex vivo immunohistology staining study. The distribution patterns of the 124I-
FIT-(PhS)2Mal [2] labeled Jurkat cells in the lung and liver tissues are similar to the non-
labeled Jurkat cells in the positive control group shown by the immunohistology staining study, 
which hints that the in vivo movability of Jurkat cells is reserved post 124I-FIT-(PhS)2Mal [2] 
labeling.  
One possible concern is the low radioactivity dose of 124I-FIT-(PhS)2Mal [2] (~100 KBq/106 
cells) used in the in vivo cell tracking study, which might be a limitation to translate this new 
method to clinical applications. Although there is no clinical PET imaging data to indicate the 
optimal radioactivity dose for directly labeled cell tracking in human, one ongoing clinical trial 
employs 7.4-18.5 MBq of 89Zr-labeled leukocytes to track peripheral immune cell infiltration 
of the brain in patients with central inflammatory disorders over 6 days.27 Moreover, in a recent 
89Zr-labeled natural killer (NK) cell (~1.5 x 108) tracking study in rhesus macaques (~6.6 Kg), 
clear PET images were acquired with only 2.0 MBq of radioactivity over 7 days.28  
Given the very similar positron abundance of iodine-124 (22.5%) and zirconium-89 (22.7%), 
longer half-life of iodine-124 (4.2 days) than zirconium-89 (3.3 days), and excellent iodine-
124 retention of 124I-FIT-(PhS)2Mal [2] labeled cells, it is a reasonable estimate that this novel 
iodine-124 based cell labeling method could provide a sufficient radioactivity dose (~20 MBq 
in 2 x 108 cells) for directly labeled cell tracking with PET in clinical trials.  
Additionally, the latest ultra-sensitive total-body PET scanner requires a very low radioactivity 
dose to achieve the same signal-to-noise ratio comparing to the current clinical PET scanners. 
For example, in the first human PET imaging study with the EXPLORER Total-Body PET 
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Scanner, high quality full-body PET images were acquired by using only 25 MBq of 18F-FDG 
(1/15 of the normal radioactivity dose) in 10 min.29 Therefore, we anticipate that the 
radioactivity dose will not be a barrier to translate 124I-FIT-(PhS)2Mal [2] to clinical cell 
tracking. 
CONCLUSION 
Two dual PET and fluorescent labeling reagents, 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] 
were prepared in excellent RCYs and evaluated for cell conjugation. The cell labeling 
efficiency of 124I-FIT-(PhS)2Mal [2] is significantly better than 124I-FIT-Mal [1]. 124I-FIT-
(PhS)2Mal [2] was used to successfully label various cell lines through their membrane thiols 
in 22%-62% labeling efficiency with prolonged radiolabel retention. Cell membrane 
localization of 124I-FIT-(PhS)2Mal [2] was confirmed by confocal fluorescence imaging. 
Longitudinal monitoring of the in vivo distribution and migration of 124I-FIT-(PhS)2Mal [2] 
labeled Jurkat cells was achieved with PET/CT imaging over 7 days with excellent target-to-
background contrast. These promising results warrant future studies in which therapeutic cells 
such as anti-cancer CAR T-cells will be labeled with 124I-FIT-(PhS)2Mal [2] for in vivo tracking 
using PET/CT.       
EXPERIMENTAL SECTION  
Synthetic chemistry and radiochemistry 
General information 
1H and 13C NMR spectra were recorded at RT on a Bruker Avance 400 instrument operating at 
the frequency of 400 MHz for 1H and 100 MHz for 13C. Chemical shifts are reported in ppm 
relative to chloroform (δ 7.26, s), dimethyl sulfoxide (δ 2.48, m) or methanol (δ 3.49, s and 
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1.09, s) and coupling constants (J) are given in Hertz. HPLC analysis was performed with an 
Agilent 1200 HPLC system equipped with a 1200 series diode array detector and a 1200 series 
fluorescence detector (G1321A). Radio-HPLC analysis was performed with an Agilent 1200 
HPLC system equipped with a series diode array detector and Raytest GABI Star radioactivity 
detector. The radiochemical purity of 124I-FIT-Mal and 124I-FIT-(PhS)2Mal was determined 
using radioHPLC and it is greater than 95% (Figure S2 and S4). Reductant free [124I]NaI was 
purchased from Perkin Elmer (product number NEZ309) in 0.02 M NaOH (pH 14) aqueous 
solution. All reagents were purchased from Sigma-Aldrich and were used without further 
purification.  
5-[3-(2-azidoethyl)thioureido]-fluorescein  
To a solution of fluorescein isothiocyanate isomer I (0.50 g, 1.28 mmol) in anhydrous THF (45 
mL) at 0 ºC, the freshly prepared 2-aminoethyl azide21 solution in DCM (5 mL) was added 
under an atmosphere of N2, followed by triethylamine (0.18 ml, 1.28 mmol). The reaction 
solution was warmed to RT while stirring for 3 h. The solvents were removed in vacuo and the 
residue was purified by column chromatography (DCM, 0.1%TFA → DCM, 5% MeOH, 0.1% 
TFA) to afford the title compound as a yellow solid (0.51 g, 82%). 
1H NMR (400 MHz, MeOH-d4):  δ 8.17 (1H, s, Ar-CH), 7.79 (1H, J = 8.0 Hz, d, Ar-CH), 7.19 
(1H, J = 8.0 Hz, d, Ar-CH), 6.72 (2H, J = 8.0 Hz, d, Ar-CH), 6.68 (2H, J = 4.0 Hz, d, Ar-CH), 
6.58 (2H, J = 8.0 Hz, J’ = 4.0 Hz, dd, Ar-CH), 3.83 (2H, J = 12.0 Hz, t, CH2), 3.61 (2H, J = 
12.0 Hz, t, CH2); 13C NMR (100 MHz, DMSO-d6) d 180.8, 168.7, 162.9, 152.9, 141.0 129.3, 
128.1, 125.1, 118.2, 114.4, 110.4, 102.3, 49.3, 40.6; HRMS (EI, m/z) [M+H]+: calc. for 
C23H18N5O5S 476.1029; found: 476.1028.  
5-[3-(2-azidoethyl)ureido]-fluorescein [3] 
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To a solution of 5-[3-(2-azidoethyl)thioureido]-fluorescein (140 mg, 0.3 mmol) and pyridinium 
tribromide (190 mg, 0.60 mmol) in THF (4 mL), water (2 mL) was added dropwise and the 
resulting solution was stirred at RT for 3 h. The reaction mixture was filtered. Water (20 mL) 
was added to the filtrate and extracted with EtOAc (3 x 20 mL). The organic extracts were 
dried over MgSO4 and evaporated under vacuo. Purification by column chromatography (0-5% 
MeOH in DCM, 0.1%TFA) yielded the title compound as an orange solid (81 mg, 63%). 
1H NMR (400 MHz, DMSO-d6): δ 10.08 (2H, s, OH), 9.11 (1H, s, NH), 8.15 (1H, s, Ar-CH), 
7.63 (1H, J = 8.0, d, Ar-CH), 7.13 (1H, J = 8.0 Hz, d, Ar-CH), 6.67 (2H, s, Ar-CH), 6.56-6.51 
(5H, m, Ar-CH x 4 and NH), 3.46–3.43 (2H, m, CH2), 3.36–3.33 (2H, m, CH2); 13C NMR (100 
MHz, DMSO-d6) d 169.3, 159.9, 155.6, 152.4, 145.4, 142.5, 129.5, 127.5, 125.7, 124.7, 113.0, 
112.2, 110.4, 102.7, 83.4, 51.1, 40.0; HRMS (EI, m/z) [M+H]+: calc. for C23H18N5O6 460.1257; 
found: 460.1267. 
Non-radioactive reference compounds of the dual PET and fluorescent labeling reagents 
To a solution of copper(I) iodide (14.5 mg, 76.2 µmol) and triethylamine (10.6 µl, 76.2 µmol) 
in dry DMF (1.0 mL), bathophenanthroline (2.5 mg, 7.62 µmol) was added under an 
atmosphere of argon, followed by either N-propargyl maleimide [4] or N-propargyl-3,4-
dithiophenolmaleimide [5] (76.2 µmol), N-iodosuccinimide (25.7 mg, 114.4 µmol), and the 
5-[3-(2-azidoethyl)ureido]-fluorescein [3] (76.2 µmol). The resulting mixture was stirred at RT 
for 18 h. Water (10 mL) was added and the product mixture was extracted with EtOAc (3 x 15 
mL). The organic extracts were washed with brine and dried over MgSO4. After filtration, the 
solvent was removed under vacuo.  
127I-FIT-Mal [1]: the crude mixture was washed with cold diethyl ether (3 x 10 mL) and then 
purified with flash column chromatography on silica (0-10% MeOH in DCM) to yield the title 
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compound as an orange solid. (31mg, 56%). 1H NMR (400 MHz, DMSO-d6) d 10.11 (2H, s, 
OH), 9.24 (1H, s, NH), 8.14 (1H, s, Ar-H), 7.61 (1H, J = 8.0 Hz, d, Ar-H), 7.12 (2H, s, CH=CH), 
7.10 (1H, J = 8.0 Hz, d, Ar-H), 6.68 (2H, s, Ar-H) 6.58 – 6.53 (5H, m, Ar-CH x 4 and NH), 
4.62 (2H, s, CH2), 4.47 (2H, J = 6.0 Hz, t, CH2); 3.57 (2H, J = 6.0 t, CH2). 13C NMR (100 
MHz, DMSO-d6) d 170.8, 169.3, 159.9, 155.6, 152.4, 146.1, 145.4, 142.5, 135.3, 130.0, 129.5, 
127.4, 125.7, 124.6, 113.0, 112.2, 110.4, 102.7, 83.5, 83.4, 55.4, 50.3, 46.0. HRMS (EI, m/z) 
[M+H]+: calc. for C30H22IN6O8 721.0544; found 721.0533. 
127I-FIT-(PhS)2Mal [2]: the crude product was purified by C-18 reverse phase flash column 
chromatography using Combiflash (5 to 95% MeOH in water) to afford the title compound as 
an orange solid (32 mg, 45%).  
1H NMR (400 MHz, DMSO-d6) d 9.15 (1H, s, NH), 8.14 (1H, J = 2.0 Hz, d, Ar-H), 7.60 (1H, 
J = 8.0 Hz, J’ = 2.0 Hz, dd, Ar-H), 7.34 - 7.23 (10H, m, Ph x 2), 7.11 (1H, J = 8.0 Hz, d, Ar-
H), 6.67 (2H, J= 2.0, d, Ar-H), 6.74 – 6.43 (4H, m), 6.48 (1H, J = 11.0 Hz, t, NH), 4.65 (2H, 
s), 4.48 (2H, J = 6.0 Hz, t); 3.58 (2H, J = 11.0 Hz, J’ = 6.0 Hz, q). 13C NMR (100 MHz, DMSO-
d6) d  168.9, 165.7, 159.4, 155.0, 151.9, 145.1, 144.9, 142.0, 135.8, 130.9, 130.9, 129.1, 129.0, 
128.9, 128.1, 126.9, 125.3, 124.2, 112.5, 111.7, 109.9, 102.1, 82.9, 82.8, 49.8, 34.4; HRMS 
(EI, m/z) [M+H]+: calc. for C42H30IN6O8S2 937.0611, found: 937.0635.  
Radiolabeling  
Copper (II) chloride (3.4 mg, 25.3 µmol), triethylamine (4.4 µL, 31.5 µmol, 1.38 equiv.), and 
bathophenanthroline (850 µg, 2.5 µmol, 10 % mol) were mixed in anhydrous acetonitrile (500 
µL). The resulting suspension (62.5 µL) was added to either N-propargyl maleimide [4] or N-
propargyl-3,4-dithiophenolmaleimide [5] (3.1 µmol) in anhydrous DMF (62.5 µL). The 
resulting red suspension (40 µL) was added to a mixture of 5-[3-(2-azidoethyl)ureido]-
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fluorescein [3] (1.0 µmol) and triethylamine hydrochloride (TEA·HCl) (16.5 µg, 0.12 µmol) 
in acetonitrile (20 µL) and [124I]NaI (~12 MBq) in 0.02 M NaOH solution (6.0 µL).  
124I-FIT-Mal [1]: after incubation at RT for 18 h, the reaction mixture was quenched with 
DMSO (100 µL) followed by water/MeOH (4:1, 1.0 mL). The resulting solution was purified 
by HPLC using a ZORBAX column (300SB-C18, 9.4 X 250 mm, 5 µm) with the following 
eluent: water (0.1% TFA) as solvent A and methanol (0.1% TFA) as solvent B, went from 30% 
B to 47.5% B in 5 min, kept at 47.5% B for 20 min, went to 90% B in 5 min, and went back to 
30% B in 5 min with a flow rate of 2.5 mL/min. The retention time of the title compounds was 
20.4 min. 
124I-FIT-(PhS)2Mal [2]: after incubation at 60 ºC for 90 min, the reaction mixture was quenched 
with DMSO (100 µL) followed by water/MeOH (4:1, 1.0 mL). The resulting solution was 
purified by HPLC using a ZORBAX column (300SB-C18, 9.4 X 250 mm, 5 µm) with the 
following eluent: water (0.1% TFA) as solvent A and methanol (0.1% TFA) as solvent B, went 
from 70% B to 75% B in 15 min, increased to 90% B in 5 min, and went back to 70% B in 5 
min with a flow rate of 2.5 mL/min. The retention time of the title compounds was 12.4 min. 
The identity of both dual labeling reagents was confirmed by co-eluting with their 
corresponding non-radioactive reference compounds (Figure S2 and S4). Formulation: the 
HPLC eluent containing the dual labeling reagent was diluted to 15% MeOH in water and was 
loaded on either a pre-conditioned Waters C18 light Sep-Pak cartridge for 124I-FIT-Mal [1] or 
Waters t-C18 Sep-Pak cartridge for 124I-FIT-(PhS)2Mal [2]. After washing with water (5 mL), 
the dual labeling reagent was released using EtOH. The EtOH was removed by a stream of N2 
and then the dual labeling reagent was re-dissolved in DMSO for further use.  
Log D measurement 
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The lipophilicity of 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2] was determined by a 
conventional partition method between n-octanol and PBS, pH 7.4. The n-octanol was saturated 
with PBS before use. The 124I-FIT-Mal [1] or 124I-FIT-(PhS)2Mal [2] (1 µL, ~2 KBq) in DMSO 
was added to a mixture of PBS (200 µL) and n-octanol (200 µL) in a 1.5 mL Eppendorf vial 
(n=6). The mixture was vigorously agitated at RT for 5 min and then centrifuged at 3000 g for 
10 min. A 100 µL aliquot from each layer was drawn for measurement in a gamma counter.  
Cell culture  
T-cells were isolated from peripheral blood samples taken from healthy volunteers aged 18 – 
45 (KCL ethics approval: HR-18/19-8846) via Ficoll separation. Blood was slowly added to a 
50 mL Falcon tube containing 15 mL of Ficoll-Paque (GE Healthcare) solution and spun in a 
centrifuge at 500 g for 25 minutes. The peripheral blood mononuclear cell layer was extracted 
and the cells were washed twice with PBS and prepared for activation. Cells were re-suspended 
in RPMI 1640 cell growth medium at a concentration of 3 x 106 cells/mL and plated on a 6-
well plate (4 mL per well). T-cells were activated with 5 µg/mL of phytohemagglutinin (PHA-
L, Sigma-Aldrich). IL-2 (100 U/mL, PeproTech) and fresh medium were added every 2-3 days.  
Jurkat and murine myeloma 5T33 (generous gift from Dr Yolanda Calle-Patino) cells were 
cultured in RPMI-1640 medium supplemented with 10% FBS, 200 U/L penicillin, 0.1 g/L 
streptomycin and 2 mM ʟ-glutamine. The cell concentration was maintained in 1 x 105~1 x 106 
cells/mL in a humidified chamber containing 5% CO2 at 37 oC.  
Cell labeling 
For 124I-FIT-Mal [1] and 124I-FIT-(PhS)2Mal [2]: suspension cells (5 x 106, n=3) were either 
treated with TCEP (1.0 mL, 1.0 mM) in PBS or PBS (1 mL) only and kept in RT for 15 min 
before washing with PBS (3 x 1.0 mL). The cells were re-suspended in PBS (0.5 mL) and 
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followed by the addition of 124I-FIT-Mal [1] or 124I-FIT-(PhS)2Mal [2] (~3 MBq) in DMSO (5 
µL). After incubation at 37 °C for another 30 min, the cells were centrifuged (1200 rpm, 5 min), 
the supernatants were transferred to new Eppendorf tubes. The pellets were further rinsed with 
PBS (2 x 0.5 mL) before being transferred to new Eppendorf tubes and re-cultivated in 
complete medium. To determine the cell labeling efficiency, the supernatants and the washes 
for each sample were combined. The pellets, supernatants, and Eppendorf tubes used for cell 
labeling were measured by a Capintec CRC®-25R dose calibrator (Capintec Inc, USA). 
For the non-radioactive reference compound of 124I-FIT-(PhS)2Mal [2]: suspension cells (2 x 
106, n=3) were treated with TCEP (1.0 mL, 1.0 mM) in PBS and incubated at RT for 15 min 
before being washed with PBS (3 x 1.0 mL) to remove TCEP. The cells were then re-suspended 
in PBS (1.0 mL) and the nonradioactive reference compound of 124I-FIT-(PhS)2Mal [2] in 
DMSO (0.5 µL, 2.0 mM) was added to achieve the final concentration of 1.0 µM. The cells 
were incubated at 37 °C for another 30 min. Hoechst 33342 in DMSO (2 µL, 250 µM) was 
added to the cells 5 min before the end of incubation. The cells were centrifuged (1200 rpm, 5 
min), the supernatants were removed and the pellets were further rinsed with PBS (3 x 1.0 mL). 
The sample was then fixed with 4% paraformaldehyde at RT for 10 min in darkness. Following 
fixation step, the cells were washed with PBS (3 x 1.0 mL) and re-suspended in PBS (50 µL). 
The cell sample (10 µL) was mounted on a microscopic glass slide, covered with a coverslip, 
and sealed with transparent nail enamel. High-resolution confocal fluorescence images were 
obtained with a Leica TCS SP5 II confocal microscope (Leica Microsystems Ltd) system and 
processed using LAS AF Lite (ver 2.6.3, build 8173, Leica Microsystems Ltd). 
Excitation/emission wavelengths were 495/517 nm and UV/455 nm for FITC and Hoechst 
33342, respectively. 
Iodine-124 retention and cell viability post radiolabeling  
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Both the 124I-FIT-(PhS)2Mal [2] labeled and untreated control Jurkat cells were maintained at 
0.2-1.0 x 106 cells/mL in complete cell media. To determine the retention of iodine-124, the 
124I-FIT-(PhS)2Mal [2] labeled Jurkat cells (0.5 mL) was collected daily. After centrifugation 
at 1500 rpm for 5 min, the supernatant and the pellet were separated and gamma counted using 
a Wallac WizardTM 1480 automatic gamma counter (Perkin Elmer, USA). Trypan Blue was 
employed to measure the cell viability. The number of live and dead cells were counted and 
the percentage of the cell viability was calculated. The experiments were conducted in 
triplicates. The data were analyzed using GraphPad Prism 7 software.  
Cell proliferation assay   
The effect of radiolabeling on cellular proliferation was assessed using the Cell Counting Kit-
8 (CCK-8). Both the 124I-FIT-(PhS)2Mal [2] labeled (~100 KBq/106 cells) and unlabeled Jurkat 
cells were maintained in complete cell media at an initial concentration of 0.2 x 106 cells/mL. 
The culture medium was replaced daily. The CCK-8 assay was performed in triplicate daily 
for 7 days. In general, 10 µL of the CCK-8 solution was added to 100 µL aliquots of either the 
labeled or unlabeled Jurkat cells; then the absorbance at 450 nm was measured with 
a SpectraMax 190 absorbance microplate reader (Molecular Devices, USA) after incubation at 
37 °C for 3 hours. The experiments were conducted in triplicate. Results are presented as mean 
± SD. 
Cell function assay 
Both the 124I-FIT-(PhS)2Mal [2] labeled (~100 KBq/106 cells) and unlabeled Jurkat cells were 
maintained at 0.2-1.0 x 106 cells/mL in complete cell media. The labeled or unlabeled Jurkat 
cells (1.0 x 106 cells/mL) were seeded into a 96 well-plate (100 µL/well) in triplicate. 12-O-
tetradecanoylphorbol 13-acetate (PMA) (30 ng/mL)/ionomycin (0.75 µg/mL) or cell media as 
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negative control were added to the Jurkat cells and incubated for 24 hrs. Supernatant samples 
(30 µL/well) were analysed by ELISA using human IL-2 Ready-SET-Go ELISA® kits from 
eBioscience (Hatfield, UK), according to the manufacturer's instructions. Absorbance at 450 
nm and 570 nm were recorded using a SpectraMax 190 absorbance microplate reader and mean 
absorbance of each sample at 450 nm was subtracted from absorbance at 570 nm. This protocol 
was repeated every other day for 6 days. The experiments were conducted in triplicates. Results 
are presented as the mean ± SD.  
In vivo PET imaging and biodistribution studies 
All animal experiments complied with the ARRIVE guidelines, the Animals (Scientific 
Procedures) Act (UK 1986), and Home Office (UK) guidelines and were conducted under a 
Home Office licence (P9C94E8A4) with local ethical approval by the KCL College Research 
Ethics Committee (CREC). 
Preclinical PET/CT images were acquired using a NanoScan PET/CT (Mediso, Budapest, 
Hungary) scanner with mice under 2% isoflurane in oxygen anesthesia. Drinking water 
containing potassium iodide (0.1%, w/v) were provided to male NSG mice (n=7) for one week 
before and throughout the PET/CT imaging experiments. On day eight, they were randomly 
divided into two groups received either the 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells (~0.5-
1.0 x 107, ~0.5-1.0 MBq, n=3) in PBS or 124I-FIT-(PhS)2Mal [2] (~0.7 MBq, n=4) in PBS (100 
µL) with 5% DMSO via tail vein injection. PET scanning was performed for 60 min either at 
4, 24 h, 2, 4, and 7 days post Jurkat cell inoculation or at 24 h post 124I-FIT-(PhS)2Mal [2] 
injection followed by a 15 min CT scan. All PET/CT data were reconstructed with the Monte 
Carlo-based full-3D iterative algorithm Tera-Tomo (Mediso Medical Imaging Systems, 
Budapest, Hungary). Raw PET data were reconstructed into 60-min bins using reconstruction 
settings (4 iterations, 6 subsets, 0.4×0.4×0.4 mm3 voxel size) as well as intercrystal scatter 
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correction. All reconstructed data were analyzed with VivoQuant software (v3.0, inviCRO, 
LLC, Boston, USA). All animals were euthanized by cervical dislocation at the end of the last 
PET/CT scan. The major thoracoabdominal organs, brain, blood, urine, left femur, and thigh 
muscle were harvested, weighed, and gamma-counted. The radioactivity in each organ was 
expressed as % ID/g. The total injected dose was defined as the sum of the whole body counts 
excluding the tail.  
Immunohistochemistry 
Three cryosections (10 µm thick) were prepared from the liver and lung of NSG mice (n=3) 
one week after receiving either 124I-FIT-(PhS)2Mal [2] labeled Jurkat cells from above PET 
imaging study, PBS, or non-labeled Jurkat cells (~1.0 x 107). These tissue sections were fixed 
with acetone and dried in air. The tissue sections were then sequentially incubated with anti-
CD3 primary antibody (clone LN10, Leica #CD3-565-L-CE) and Polymer-supported 
peroxidase and anti-Mouse IgG followed by DAB treatment (MaxVisionTM2 HRP-Polymer 
anti-Mouse IHC Kit) and finally stained with hematoxylin. The tissue sections were then 
observed under an Olympus DP73 digital microscope.  
ABBREVIATIONS 
Bq: becquerel; CT: computed tomography; IV: intravenous; %ID/g: percentage injected dose 
per gram tissue; PBS: phosphate buffered saline; PET: positron emission tomography; NIS: N-
iodosuccinimide; RCYs: radiochemical yields; RT: room temperature; TCEP: tris(2-
carboxyethyl)phosphine; TEA·HCl: triethylamine hydrochloride.  
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